corvus_logo_small.jpg
Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
September 10, 2024 08:30 ET | Corvus Pharmaceuticals, Inc.
Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully approved agents for the treatment of relapsed PTCL and...
corvus_logo_small.jpg
Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024 16:05 ET | Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D.,...
Figure 1
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
August 06, 2024 16:01 ET | Corvus Pharmaceuticals, Inc.
Early Results from Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Demonstrate Clinical Activity and Corresponding Changes in Cytokine Levels Consistent with ITK Inhibition Mechanism of...
corvus_logo_small.jpg
Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
August 01, 2024 08:30 ET | Corvus Pharmaceuticals, Inc.
Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024 Fast track designation underscores unmet need for patients with relapsed or refractory PTCL,...
corvus_logo_small.jpg
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024
July 31, 2024 08:30 ET | Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference...
corvus_logo_small.jpg
Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment of Inflammatory Diseases
July 25, 2024 08:30 ET | Corvus Pharmaceuticals, Inc.
Data demonstrated in vitro and in vivo ITK inhibition with soquelitinib induced switching of proinflammatory Th17 cells into anti-inflammatory Treg cells Publication confirms and extends...
corvus_logo_small.jpg
Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference
May 30, 2024 16:02 ET | Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president...
Figure 1
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
May 06, 2024 16:01 ET | Corvus Pharmaceuticals, Inc.
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024 Soquelitinib Registration Phase 3 Trial in Peripheral T Cell...
corvus_logo_small.jpg
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
May 02, 2024 16:02 ET | Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference...
corvus_logo_small.jpg
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
May 02, 2024 08:30 ET | Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today...